Premature adrenarche (PA) often leads to significant concerns regarding skeletal maturation in young patients. A recent 2026 study investigated premature adrenarche bone age advancement specifically within non-obese children. Researchers reviewed the medical records of 84 children to differentiate the impact of adrenal androgens from obesity-related growth factors. Consequently, they found that while bone age does advance, the impact on final predicted height is often manageable. This study provides crucial data for pediatricians managing growth expectations in children with early androgen exposure.

The study participants had a mean age of 7.41 years, and the majority were female. Interestingly, the mean difference between bone age and chronological age was 0.59 years. Furthermore, children with a bone age advancement of one year or more typically exhibited a higher height standard deviation score (SDS). In contrast, serum DHEA-S levels did not show a significant difference across various bone age advancement groups. Therefore, linear growth status appears more closely linked to skeletal maturation than circulating adrenal androgen levels alone.

Monitoring Premature Adrenarche Bone Age

Most patients in the research cohort maintained a predicted adult height (PAH) within their genetic target range. However, clinicians should note that approximately 20% of the children had PAH values below their calculated mid-parental height. Consequently, regular monitoring of growth velocity remains essential for this specific subgroup. Pediatricians should evaluate clinical growth parameters alongside radiological data to provide accurate prognostic counseling to families. Moreover, understanding that bone age maturation in non-obese children follows a distinct path from obese peers helps in avoiding over-treatment. Specifically, the independent contribution of linear growth to bone age suggests that height SDS is a more reliable predictor of skeletal advancement than hormonal markers.

Frequently Asked Questions

Does premature adrenarche lead to short stature in non-obese children?

In most cases, non-obese children with premature adrenarche achieve a predicted adult height within their genetic target range. However, roughly 20% may show a lower predicted height than their mid-parental average, necessitating long-term growth monitoring.

What is the primary driver of bone age advancement in PA?

Current research suggests that bone age advancement in non-obese children with premature adrenarche is more closely associated with the child's current linear growth status (height SDS) than with specific serum DHEA-S concentrations.

How often should bone age be assessed in children with PA?

Clinical practice often involves an initial bone age assessment at diagnosis. Follow-up scans are typically performed if there is a significant acceleration in growth velocity or if the initial advancement was greater than one year.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Çiftci N et al. Bone age advancement in non-obese children with premature adrenarche: relationship to growth acceleration and predicted adult height outcomes. J Pediatr Endocrinol Metab. 2026 Mar 17. doi: 10.1515/jpem-2025-0695. PMID: 41843914.

2. Uli NK et al. Decoding Bone Age in Premature Adrenarche Challenges. Pediatric Research. 2026; doi:10.1038/s41390-026-00456-x.

3. Heiskanen N et al. Predicted Adult Height Remained Normal in Children With Premature Adrenarche Despite Advanced Bone Age. Acta Paediatrica. 2025;114(12):2450-2458.